Juries in three cases have found that Monsanto’s weedkiller Roundup causes cancer, most recently resulting in a $2 billion verdict. And based on the argument used in that case, the safety of glyphosate—Roundup’s key ingredient—may not be the key issue moving forward.
If you thought the Takata airbag recall was over, think again. What the U.S. National Highway Traffic Safety Association (NHTSA) calls “the largest and most complex safety recall in U.S. history” is ongoing, nearly five years after it was first announced.
If you’re planning a trip abroad — particularly to countries with high rates of violence, disease, or both — you need to know about travel health insurance.
Paying an accounting professional can have benefits that far outweigh the added costs—but what happens if your accountant makes a mistake? If your accountant made a costly error and is unwilling to set things right, you should understand your legal rights and options.
Pharmaceutical companies approach new drugs with one question in mind: How do we make $1 billion? A compound’s path from initial approval to blockbuster drug typically follows these eleven steps.
Litify is the best-in-class technology solution that will transform your law firm into a more successful practice. By leveraging the power of technology to simplify daily tasks, Litify gives law firms the tools they need to become high-performing businesses.
Hacking of real estate transactions increased more than 50-fold last year. Learn how to protect yourself.
Bayer and Monsanto are trying to sell their proposed merger as being in the public interest, but the evidence simply doesn't support this claim. Here's why.
After stalling in the New York State Legislature for more than a decade, a bill that would help provide justice for child victims of sexual abuse is once again on the agenda.
Once again, governments are suing big companies to recoup the costs of a public health crisis caused by an addictive drug. But how do these lawsuits differ?
Here are the tactics Big Pharma uses to ensure that a new product becomes the next $1 Billion drug.